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Abstract
A population-based study was performed to investigate the efficacy of mecillinam treatment of community-acquired
urinary tract infections (CA-UTI) caused by extended-spectrum b-lactamase (ESBL) producing Escherichia coli. The study was
conducted in South-Eastern Norway. Data from patients with CA-UTI caused by ESBL-producing and non-producing
(random controls) E. coli were collected through interviews, questionnaires, medical records and the Norwegian Prescription
Database. Treatment failure was defined as a new antibiotic prescription appropriate for UTI prescribed within two weeks
after the initial antimicrobial therapy. Multivariable logistic regression analysis was performed to identify treatment agents
and patient- or bacterial traits associated with treatment failure. A total of 343 patients (mean age 59) were included, of
which 158 (46%) were treated with mecillinam. Eighty-one patients (24%, mean age 54) had infections caused by ESBL
producing E. coli, and 41 of these patients (51%) received mecillinam as the primary treatment. Mecillinam treatment failure
was observed in 18 (44%) of patients infected by ESBL-producing strains and in 16 (14%) of patients with a CA-UTI caused
by ESBL non-producing strains. Multivariable analysis showed that ESBL status (odds ratio (OR) 3.2, 95% confidence interval
(CI) 1.3–7.8, p = 0.009) and increased MIC of mecillinam (OR 2.0 for each doubling value of MIC, CI 1.4–3.0, p,0.001) were
independently associated with mecillinam treatment failure. This study showed a high rate of mecillinam treatment failure
in CA-UTIs caused by ESBL producing E. coli. The high failure rate could not be explained by the increased MIC of mecillinam
alone. Further studies addressing the use of mecillinam against ESBL-producing E. coli, with emphasis on optimal dosing
and combination therapy with b-lactamase inhibitors, are warranted.
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Introduction
Escherichia coli is the most common cause of community-acquired
urinary tract infection (CA-UTI). The worldwide dissemination of
multidrug resistant CTX-M extended spectrum b-lactamase
(ESBL)-producing E. coli has significantly limited the oral
treatment options for CA-UTI [1]. Mecillinam is an amidinope-
nicillin with selective activity against Gram-negative bacteria and
Enterobacteriaceae in particular. It is widely used in the Scandinavian
countries, but the guidelines regarding dosage varies between
countries with 200 mg thrice daily (TID) usually prescribed in
Norway. In vitro data suggest that mecillinam has a favourable
stability to b-lactamase hydrolysis compared with other penicillins
[2]. International treatment guidelines endorse the use of
mecillinam with an A1-grading of recommendation as a first
choice treatment for uncomplicated lower urinary tract infection
in women [3]. Mecillinam can be administered per os as a
prodrug, the pivaloyloxymethyl ester pivmecillinam, which after
absorption is converted to the antibacterial active mecillinam [4].
Mecillinam has been shown to exert a minor ecological impact on
the human commensal flora [5,6]. The favourable ecological
profile is also underlined by the observed stable and low (,2%)
rate of resistance to mecillinam in uropathogenic E. coli in repeated
international surveys as well as in Scandinavian countries with a
widespread use of pivmecillinam over many years [7,8].
In vitro antimicrobial susceptibility tests have provided favour-
able results for mecillinam against CTX-M producing E. coli [9–
12]. However, a clavulanate reversible inoculum dependent effect
that significantly increases the minimum inhibitory concentration
(MIC) for mecillinam in ESBL-producing E. coli compared to non-
producers has been reported [13,14]. Titelman et. al also found a
low bacteriological cure rate (two of eight patients) in a recent
study and these notions underline the need for studies addressing
the clinical efficacy of mecillinam in CA-UTI caused by ESBL
producing Enterobacteriaceae [10]. To our knowledge only case-
report studies have been reported so far [10,15].
In this population-based study we aimed to prospectively
examine the clinical efficacy of mecillinam in the treatment of
CA-UTI caused by ESBL-producing E. coli compared to non-
ESBL-producing E. coli.
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Patients and Methods
Ethics Statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics – South East (‘‘REC South
East’’), following the Declaration of Helsinki principles (reference
number: 2009/2037 BS-08901b). It is registered in Clinical-
Trials.gov (Identifier: NCT01838213).
Setting and Design
This study was part of an investigation of CA-UTI and faecal
carriage of ESBL-producing bacteria conducted in Norway at the
Department of Medical Microbiology, Vestre Viken Hospital
Trust, between February 2009 and May 2012 [16]. The hospital
trust serves approximately 450.000 inhabitants and is situated in a
mixed urban, suburban and rural area in the South-Eastern part
of the country. Our two laboratories analyze in- and outpatient
samples from this area.
Patients with any type of CA-UTI caused by ESBL-producing
or non-ESBL producing E. coli and receiving empirical treatment
were included in the study. Data on treatment outcome were
obtained and possible associations between outcome and mecilli-
nam treatment, ESBL-status and other variables were investigated.
Participants
The eligible population constituted all patients $18 years old
with a urine culture yielding E. coli .10,000 CFU/ml. We
excluded patients who: i) had not been empirically treated (i.e., did
not collect an antimicrobial agent appropriate for UTI (trimeth-
oprim, trimethoprim-sulfamethoxazole, ciprofloxacin, ofloxacin,
nitrofurantoin, pivmecillinam, amoxicillin or cephalexin) at a
Norwegian pharmacy at the index date (fosfomycin and amoxi-
cillin/clavulanate are not available in Norway), ii) had lived in
Norway for ,1 year, iii) were unable to answer the questionnaire,
iv) had previously diagnosed infection caused by ESBL-producing
bacteria, or v) had health care associated UTI (i.e., had been
hospitalized or residing in a nursing home for .24 hours during
the last 31 days).
Procedures for inclusion of participants and data collection have
been described earlier [16]. In brief, participation required a
written consent; all eligible patients with an ESBL-producing E.
coli were invited to participate. For each patient with an ESBL-
producing E. coli invited, 2–5 patients with non-ESBL E. coli urine
isolates during the same time period were randomly selected
(ExcelH randomization, Microsoft, Redmond, WA) and invited to
participate. Participants answered standardized questionnaires
which included queries about the current UTI, previous UTIs,
contact with the health care system, catheter use and adherence to
antibiotic prescriptions. Detailed data about antimicrobial drugs
dispensed were collected from The Norwegian Prescription
Database and from medical records [17]. To quantify the number
of UTIs for each patient in the preceding year, the number of
prescriptions of three antimicrobial agents–trimethoprim, mecilli-
nam, and nitrofurantoin–were counted in individual patients. In
Norway, these agents are first choices for UTI treatment and are
not prescribed for other infections.
Microbiological Data and Antibiotic Susceptibility
Urine cultivation and bacterial identification were performed
using ChromID CPS3 agar and the VITEK-2 system (both
BioMerieux, Marcy l’Etoile, France). Antimicrobial susceptibility
testing and interpretations including ESBL screening were
performed using VITEK-2 (AST- N029, N122 or N209 card)
which reports MIC of mecillinam in categories #1, 2, 4, 8, 16, 32
and $64 mg/L based on measurements in wells with mecillinam
concentrations of 1, 3, 8 and 32 mg/L. All isolates resistant to
cefpodoxime, cefotaxime or ceftazidime were selected for confir-
matory ESBL testing using the Etest gradient system (AB-Biodisk,
BioMerieux). Clinical breakpoint interpretations were according to
EUCAST. The breakpoint for resistance for mecillinam in E. coli
was .8 mg/L during the study period [18].
Molecular Detection of ESBL
ESBL genotype analysis was performed using PCR for blaCTX-M
detection and group assignment, as described [19]. Detection of
blaTEM and blaSHV was performed on ESBL-positive isolates
negative for blaCTX-M using consensus PCR followed by DNA
sequencing [20].
Treatment Outcome Measures
Two different treatment failure measures were obtained and
compared: i) a patient receiving a second antibiotic prescription
appropriate for UTI (same antibiotics as in inclusion) within day
1–14 after the index date [21–23] ii) a patient reporting not to
have been subjectively cured within 14 days after initial treatment.
Statistical Analysis
The statistical analyses were conducted using PASW statistics
software, version 19.0 (IBM SPSS, Chicago, IL). Univariate
analyses were performed using logistic regression, Pearson chi
square, Fisher’s exact test, Student’s t-test or the Mann-Whitney
U-test as appropriate. The association between variables and
treatment failure was quantified by odds ratio (OR) with 95%
confidence interval (CI). Variables with a p,0.15 were considered
candidates for the multivariable model. A manual backward
stepwise elimination procedure using multivariable logistic regres-
sion was performed to identify independent risk factors for
treatment failure. Multivariable analyses were preceded by
estimation of correlation between risk factors and followed by
testing of all initial variables added to the final model. All p-values
were two-tailed, and a p-value of ,0.05 was considered
significant. The two outcome measures were compared using
Cohens kappa.
Results
A total of 478 (1.5%) of approximately 32.000 urine samples
analysed during the inclusion period yielded an ESBL-producing
E. coli. Of these 478 samples, 231 (48%) were from ineligible
patients (mostly because of earlier ESBL and contact with the
health care system) and 247 (52%) were from eligible patients. Of
these, 132 (53%) consented to participate, but 49 (37%) had not
received an antimicrobial at index date and 2 were ineligible for
other reasons leaving 81 participants. Among 1330 randomly
selected patients with non-ESBL UTI, 453 (34%) consented to
participate. Of these, 185 (41%) had not received an antimicrobial
drug at index date and six were ineligible for other reasons leaving
262 participants with non-ESBL UTI.
Participants
The study population had a mean age of 59 years (range 18–93
years), which was comparable to that of all patients invited to
participate (62 years). In total, 87% of the participants were
female. The mean age of patients with an ESBL-producing E. coli
was 54 years (range 18–92 years), which was significantly younger
than patients with a non-ESBL-producing strain (61 years). There
were no significant differences between patients with ESBL-
positive or ESBL-negative UTI in relation to gender, prescribed
Mecillinam Treatment of ESBL-Producing E. coli
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treatment (type or duration) or number of urinary tract infections
during the past year.
Antibiotic Susceptibility
An overall higher prevalence of antimicrobial-resistance was
detected in ESBL-producing strains than in non-producers
(Table 1). The MIC of mecillinam in ESBL-producing strains
was higher than in non-ESBL producing strains (2 mg/L (inter-
quartile range (IQR) 0 to 4 mg/L) vs. #1 mg/L (IQR #1 to
#1 mg/L), p,0.001).
Molecular Detection of ESBL
PCR and sequence analyses showed that 68%, 28%, and 2.5%
of the ESBL isolates belonged to the CTX-M group 1, CTX-M
group 9 and SHV group 5/12, respectively. One ESBL-isolate was
not available for ESBL-typing. TEM-type ESBLs were not
detected.
Treatment Outcome Measures
Information on repeat prescriptions (interpreted as treatment
failure) were available from the Norwegian Prescription Database
and medical records for all participants (n = 343). Clinical data to
assess the clinical outcome were available for 251 patients (73%)
only. The participants with missing information on the clinical
outcome were evenly distributed between the ESBL-positive and
ESBL-negative groups. There was substantial agreement between
the two outcome measures with Cohen’s kappa = 0.70 and
congruent results in 219 (87%) of cases evaluable with both
methods [24]. Due to the completeness of data, results based on
the prescription registry (repeat prescriptions) will be presented
henceforth.
Treatment Outcome
In total, 101 (29%) treatment failures as determined by repeat
prescriptions were recorded, of which 73 (72%) occurred within
the first seven days after initiation of treatment. The treatment
failure rate was higher among patients with an ESBL-positive
strain (53%) than an ESBL-negative strain (22%) (p,0.001).
There were no significant differences in treatment outcome
between the different ESBL genotypes.
Treatment outcomes were compared between patients treated
with mecillinam (mecillinam-group) and those treated with other
antimicrobials (non-mecillinam group). The two groups were
similar with regard to background characteristics with the
exception of gender and prescribed dose. Females were given
mecillinam treatment more frequently than males (49% vs. 23%,
respectively, p = 0.001). The mean dose of antimicrobial agent
dispensed for the actual UTI was 8.3 defined daily doses (DDD) in
the mecillinam group as compared to 6.1 DDD in the non-
mecillinam group (p,0.001). Approximately 75% of the patients
received a prescription for seven days or more as judged from the
number of DDDs. Self-reported compliance with prescribed
antibiotics exceeded 90% in both treatment groups.
In the mecillinam treatment group the rate of treatment failure
among patients with ESBL-producing strains was 44% vs. 14% for
patients with non-ESBL producers (Figure 1). Age, the strain’s
ESBL status, MIC of mecillinam and overall resistance profile
were associated with treatment failure (Table 2). Treatment failed
in all four patients with strains that were in vitro resistant to
mecillinam (3 ESBL-positive strains and 1 ESBL-negative strain).
In contrast, we observed a much lower rate of treatment failure
(20%) in patients (n = 15) with ESBL-producing strains with a low
mecillinam MIC (#1 mg/L).
In the non-mecillinam treatment group the overall prevalence
of treatment failure among patients with and without ESBL-
producing strains was 63% and 29%, respectively. Furthermore,
the prevalence of treatment failure was 85% and 16% in patients
who received an antimicrobial for which their strain was in vitro
resistant or non-resistant, respectively. In vitro resistance to the
dispensed antimicrobial agent (i.e., inappropriate initial treat-
ment), ESBL status and overall resistance profile were associated
with treatment failure (Table 3).
Multivarible Analysis
Results from the multivariable analysis are presented in Table 4.
The multivariable analyses were performed separately on each of
the two treatment groups.
Mecillinam treatment group. The ESBL status and the
strain’s MIC of mecillinam were both retained in the final model,
and thus associated with treatment failure. An ESBL-producing
strain was associated with a three-fold risk, and each doubling of
mecillinam MIC (from #1 mg/L), was associated with a two-fold
risk of treatment failure. Thus, the treatment failure rate for
ESBL-positive strains was substantially greater than for ESBL-
negative strains expressing the same mecillinam MIC (Figure 1).
Non-mecillinam treatment group. Inappropriate initial
treatment was the only variable retained in the final model and
was strongly associated with treatment failure. If this variable was
omitted from analysis, the final model would include ESBL status
(OR = 2.4, CI 1.03–5.5, p = 0.04), trimethoprim resistance
Table 1. Prevalence of resistance in ESBL-producing and non-ESBL-producing E. coli.
Resistance to ESBL-producing E. coli (n = 81) Non-ESBL-producing E. coli (n = 262) p-value
Ampicillin 100% 40% ,0.001
Mecillinam 6.2% 0.4% 0.001
Trimethoprim 74% 29% ,0.001
Trimethoprim-sulfamethoxazole 72% 27% ,0.001
Nitrofurantoin 1.2% 0.0% 0.24
Ciprofloxacin 53% 7.7% ,0.001
Gentamicin 38% 5.2% ,0.001
Cefuroxime 98% 2.4% ,0.001
Cefotaxime 98% 0% ,0.001
doi:10.1371/journal.pone.0085889.t001
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(OR = 6.4, CI 3.1–13.2, p,0.001) and treatment with nitrofuran-
toin (OR = 0.25, CI 0.08–0.8, p = 0.02).
The results of the multivariable analysis did not change
significantly when i) the four patients with in-vitro mecillinam
resistant microbes were excluded from the analysis in the
mecillinam treatment group in the final model, ii) participants
with a recent (#1 month) history of UTI were excluded or iii)
when the variables age, gender and number of UTIs during the
past year were included in the final model.
Discussion
To our knowledge this is the first population-based study on the
clinical efficacy of mecillinam in CA-UTI. We observed a
significantly higher rate of mecillinam treatment failure in patients
with a CA-UTI caused by ESBL-producing E. coli compared to
non-ESBL-producing strains. The ESBL-producing strains were
dominated by CTX-M type 1 and 9, in accordance with the
current national and international situation [25,26].
There are several possible explanations for the high rate of
mecillinam treatment failures in ESBL-producing E. coli. Firstly,
we observed that the mean MIC of mecillinam in ESBL-
producing strains was higher than in non-producers. A doubled
MIC of mecillinam was associated with a two-fold risk of
treatment failure in both univariate and multivariable analysis
(Figure 1). This observation suggests that increasing the mecilli-
nam dose or the dosing frequency might have reduced the
treatment failure rate because the bactericidal activity of
betalactam antibiotics is dependent on the time period the drug
concentration exceeds the actual MIC at the infection site [27].
This notion is also supported by urine concentration measure-
ments of mecillinam in healthy adults showing that a sensitive E.
coli population should be suppressed by mecillinam in urine
throughout a 24-h period if 400 mg pivmecillinam is given thrice
daily [28]. Only 200 mg TID was prescribed to most study
patients in accordance with Norwegian guidelines. Moreover,
Monte Carlo simulations run to predict serum concentrations after
400 mg pivmecillinam given per os TID also support a higher
dosage [29]. These simulations showed that this dose will only
achieve a serum concentration above MIC for more than 40% of
the time if MIC #0.25 mg/L. This is lower than for most ESBL-
producing strains and supports the fact that that treatment failures
can occur because of low dosing of mecillinam. Mecillinam and
active metabolites accumulate in urine and a reduced antimicro-
bial potency of mecillinam would especially occur towards bacteria
with slightly elevated MICs in upper urinary tract infections where
Figure 1. Mecillinam treatment failure rate among patients
with community-acquired urinary tract infection caused by
ESBL-producing and non-ESBL-producing E. coli with different
mecillinam mean inhibitory concentrations.
doi:10.1371/journal.pone.0085889.g001




failure n = 34
Treatment
success n = 124 Crude OR 95% CI p-value
Age in years, mean 6 SD 53617 61619 0.98 0.96–0.998 0.03
Female gender (%) 32 (94) 116 (94) 1.1 0.22–5.5 1.0
Number of urinary tract infections during past year, mean 6 SDb 1.061.4 1.261.5 0.91 0.69–1.2 0.51
Total prescribed dose of antimicrobial agent in DDD (median, IQR)c 6.7 (6.7–10) 6.7 (6.7–10) 0.82 0.66–1.0 0.13
ESBL-producing strain (%) 18 (53) 23 (19) 4.9 2.2–11 ,0.001
Mecillinam MIC (mg/L) (median IQR)d 2 (#1–4) #1 (#1–#1) 1.3 1.1–1.5 ,0.001
Strain resistant to initial treatment (mecillinam) (%) 4 (12) 0 (0) – – 0.002
Strain resistant to ampicillin (%) 26 (76) 57 (46) 3.8 1.6–9.1 0.002
Strain resistant to ciprofloxacin (%) 12 (35) 19 (16e) 3.0 1.3–7.0 0.01
aData are presented as the absolute number of patients unless specifically noted.
bTo quantify the number of UTIs for each patient in the preceding year, the number of prescriptions of three antimicrobial agents–trimethoprim, mecillinam, and
nitrofurantoin–were counted. In Norway, these agents are first choices for UTI treatment and are not used for other infections.
cOR is per increase of one defined daily dose (DDD) (One DDD = 600 mg of pivmecillinam), IQR = inter-quartile range.
dMIC = minimal inhibitory concentration.
eMissing information on two patients.
doi:10.1371/journal.pone.0085889.t002
Mecillinam Treatment of ESBL-Producing E. coli
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e85889
accumulation of mecillinam in the urine is less pronounced
[28,30,31].
The other variable found to be associated with treatment failure
in multivariable analysis was ESBL-status itself (Figure 1). This is
consistent with previous in vitro studies on the activity of
mecillinam against ESBL-producing E. coli showing that mecilli-
nam is not stable against ESBLs [2,13,14]. ESBL-producing
strains have an inoculum dependent MIC for mecillinam. Agar
dilution analyses of CTX-M producing E. coli with and without
clavulanic acid added showed a significant inoculum effect on the
MIC of mecillinam that was reversed by clavulanate [13,14]. An
inoculum of 106 CFU/spot gave an approximately 100-fold
increase in mecillinam MIC compared to the standard inoculum
(104 CFU/spot). Interestingly, recently published time-kill analyses
showed a significant bactericidal activity in only 7/48 (15%) of
CTX-M producing E. coli strains even with the addition of
clavulanic acid [13]. In vitro antimicrobial susceptibility tests are
mostly based on bacteriostatic rather than bactericidal activity and
the observed reduced bactericidal effect of mecillinam against
ESBL-producing E. coli may therefore pass unrecognised.
Our results may seem to contradict the recently published 100%
mecillinam treatment success rate in seven patients with ESBL-
producing E. coli [10]. However, six of those strains had a MIC of
mecillinam #1 mg/L while the last one had a MIC of 2 mg/L.
Among our fifteen ESBL-producing strains with a mecillinam
MIC #1 mg/L, treatment failure was only noted in three (20%).
Thus, our results are compatible with the observations made in
this small case study [10].
Other studies investigating effect of mecillinam in the treatment
of (non-ESBL) UTI have reported lower overall treatment failure
rates than ours [32,33], while others have reported comparable
results [34,35]. Several factors may have contributed to an overall






success n = 118 Crude OR 95% CI p-value
Age in years, mean 6 SD 57618 61616 0.99 0.97–1.0 0.14
Female gender (%) 54 (81) 98 (83) 0.85 0.39–1.8 0.68
Number of urinary tract infections during
past year, mean 6 SDb
1.061.8 1.161.7 0.96 0.80–1.1 0.34
Total dispensed dose of antimicrobial
agent in DDD (median, IQR)c
5.6 (4.0–7.0) 5.6 (4.5–6.3) 0.95 0.86–1.1 0.33
ESBL-producing strain (%) 25 (37) 15 (13) 4.1 2.0–8.5 ,0.001
Strain resistant to initial treatment (%) 45 (68d) 8 (6.8) 29 12–71 ,0.001
Strain resistant to ampicillin (%) 52 (78) 50 (42) 4.7 2.4–9.3 ,0.001
Strain resistant to ciprofloxacin (%) 21 (31) 11 (9.3) 4.4 2.0–10 ,0.001
Strain resistant to trimethoprim (%) 46 (69) 28 (24) 7.0 3.6–13 ,0.001
Treatment
- Treated with trimethoprim (%) 41 (61) 66 (56) 1.2 0.67–2.3 0.49
- Treated with a quinolone (%) 5 (7.5) 12 (10) 0.71 0.24–2.1 0.54
- Treated with nitrofurantoin (%) 5 (7.5) 21 (18) 0.37 0.13–1.0 0.052
- Treated with another antibiotic
(including combinations)e (%)
16 (24) 19 (16) 1.6 0.78–3.4 0.19
aData are presented as the absolute number of patients unless specifically noted.
bTo quantify the number of UTIs for each patient in the preceding year, the number of prescriptions of three antimicrobial agents–trimethoprim, mecillinam, and
nitrofurantoin–were counted. In Norway, these agents are first choices for UTI treatment and are not commonly used for other infections.
cOR is per increase of one defined daily dose (DDD). IQR = inter-quartile range.
dMissing information on one patient.
eThe other group consist of patients treated with (numbers of patients in parentheses): trimethoprim-sulfamethoxazole (16), intravenous treatment (9), amoxicillin (5),
cefalexin (3), pivmecillinam and nitrofurantoin (1) and pivmecillinam and trimethoprim (1).
doi:10.1371/journal.pone.0085889.t003
Table 4. Independent risk factors of treatment failure in the mecillinam and the non-mecillinam treatment group.
Treatment group and variable Level Adjusted OR 95% CI p-value
Mecillinam group
- ESBL-producing strain Yes/no 3.2 1.3–7.8 0.009
- Mecillinam MICa Doubling of MIC 2.0 1.4–3.0 ,0.001
Non-mecillinam group
- Strain resistant to initial treatment Yes/no 29.5 12–71 ,0.001
aFor each doubling concentration starting at 1 mg/L which is the lowest level reported by the VITEK-2 (BioMerieux) system.
doi:10.1371/journal.pone.0085889.t004
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high rate of treatment failure in the present study. Firstly, the
inclusion criteria did not exclude complicated UTIs. Secondly,
only bacteriologically verified UTIs were included. This criterion
selects towards complicated UTI as the diagnosis of sporadic CA-
UTI in women is often not supported by urine culture in Norway.
Thirdly, a large proportion of the infections were caused by ESBL-
producing strains with multiple drug resistance. Fourthly, patients
with new UTIs occurring within two weeks from the index UTI
and receiving a new prescription would have been classified as
treatment failures under this study protocol. Given that 72% of
treatment failures occurred within seven days this effect is
probably small. Finally, the mean age of the study population
was relatively high compared to other studies probably due to
indications for culturing as mentioned above [36].
Our study was observational and associations between variables
and treatment failure are therefore susceptible to bias. Only 37%
of invited patients accepted the invitation to participate in the
study and 40% of these patients did not receive empirical
treatment. We have limited information about non-participants
except for age, but assume this is a non-differential bias since both
treatment groups probably are affected the same way. Another
bias that may affect patients in different treatment groups
differently is side effects resulting in new prescriptions that will
be recorded as treatment failures. Furthermore, some patients may
have been contacted by their doctor’s practice staff when
susceptibility testing identified bacterial resistance against the
initial antimicrobial agent. This may have resulted in additional
prescription indicating initial treatment failure even if the patient
had clinical improvement. However, the significant association
between clinical outcome recorded during interviews and data
from the prescription database strongly indicates that these effects
have been limited and that change of treatment in most cases was
guided by patient symptoms. This underlines the reliability of a
repeated prescription within 14 days as a valid surrogate marker
for treatment failure. The patients were not randomized between
treatment schemes. However, it is unlikely that this has affected
the overall outcome since ESBL status was not known prior to
treatment and patients with prior ESBL-positive infection were not
included. Furthermore, the choice of treatment (type and duration)
did not seem to be affected by ESBL status (data not shown).
Finally, TEM-1 has a hydrolytic activity against mecillinam [14].
This enzyme may be present in ampicillin resistant strains
including ESBL-producing strains. The OR for mecillinam
treatment failure in non-ESBL producing ampicillin resistant
versus non-ampicillin resistant strains was 2.0 (95% CI: 0.68–5.7,
p = 0.21). Characterization of mechanisms of ampicillin resistance
or identification of possible narrow spectrum blaTEM or blaSHV
genes in ESBL-producing strains was not performed and could not
be accounted for in the analyses performed. Thus this is a potential
source of bias in the study.
Mecillinam has been proposed as an anti-ESBL agent [12]. The
present study indicates that mecillinam with the current dosing
(200 mg TID of pivmecillinam) has limited efficacy against
infections caused by ESBL-producing E. coli. Although this is an
observational study, we suggest that per oral mecillinam (i.e.
pivmecillinam) should only be prescribed in uncomplicated UTIs
caused by ESBL-producing E. coli if no other per oral options are
available. We also suggest that higher doses of pivmecillinam than
usually prescribed in Norway (200 mg TID) should be used
because of the observed MIC-dependant efficacy. This is in
particular relevant for patient at high risk of UTI caused by an
ESBL-producing strains [16]. Significantly higher doses are
manageable since pivmecillinam has a low toxicity. Our data also
suggest that the mecillinam MIC break points for ESBL-producing
E. coli should be reconsidered because of its reduced clinical
efficacy and bactericidal effect against these strains.
Importantly the study results do not affect mecillinam’s status as
a first line drug in the empirical treatment of CA-UTI. The overall
treatment failure rate was lower in patients receiving mecillinam
(22%) than for patients in the non-mecillinam treatment (36%).
This difference between the mecillinam and non-mecillinam group
was valid also with different ESBL status (44% vs. 63% treatment
failure in the ESBL group and 14% vs. 29% treatment failure in
the non-ESBL group for patients in the mecillinam group and
non-mecillinam group, respectively). This is probably because of
the high prevalence of resistance to the other first-line per oral
antibacterial drugs most commonly used against CA-UTI
(Table 1).
In conclusion, we observed a high rate of mecillinam treatment
failure in CA-UTI caused by ESBL-producing E. coli even for
in vitro sensitive strains. The treatment failure of mecillinam was
associated with ESBL-production per se as well as the increased
MIC for mecillinam in ESBL-producers. Mecillinam is ecologi-
cally favourable and has a well documented effect in CA-UTI
caused by non-ESBL producing E. coli. Further studies addressing
the use of pivmecillinam against ESBL-producing E. coli with
emphasis on optimal dosing and effect of combination therapy
with b-lactamase inhibitors seem warranted.
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